Last reviewed · How we verify
NCT04052854
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
trial testing Zanubrutinib in Waldenström Macroglobulinemia. No longer available.
Quick facts
| Lead sponsor | BeiGene |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 10 locations across United States |
Drugs / interventions tested
- Zanubrutinib (ZANUBRUTINIB) — full drug profile →
Conditions studied
- Waldenström Macroglobulinemia — all drugs for Waldenström Macroglobulinemia →
Sponsor
BeiGene — full company profile →
Who can join
18 and older, any sex, with Waldenström Macroglobulinemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter expanded access study of zanubrutinib monotherapy for participants with B-cell malignancies who are ineligible to enroll into any available zanubrutinib clinical trials
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies.
Song Y, Wu SJ, Shen Z, Zhao D, et al · · 2023 · cited 6× · PMID 37845755 · DOI 10.1186/s40164-023-00448-5 -
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States.
Castillo JJ, Kingsley EC, Narang M, Yimer HA, et al · · 2023 · cited 3× · PMID 36819162 · DOI 10.1002/jha2.619 -
A GLOBAL CONGRESS DIGEST ON WALDENSTRÖM‘S MACROGLOBULINEMIA. Report from the 11th International Workshop on Waldenström‘s Macroglobulinemia, 27th–30th October, 2022
· 2022 -
Abstract Book for the 27th Congress of the European Hematology Association
· 2022 -
P1160: RESULTS OF A PHASE 2 EXPANDED ACCESS STUDY OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
Castillo J, Kingsley E, Narang M, Yimer H, et al · · 2022
Verify or expand the search:
- PubMed search for NCT04052854
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Zanubrutinib
Trials testing the same drug.
- NCT07341191 — Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR · Phase 2 · not yet recruiting
- NCT06859008 — Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Rel · Phase 1 · recruiting
- NCT07377578 — A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cel · Phase 3 · recruiting
- NCT07321652 — Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C · Phase 3 · not yet recruiting
- NCT07283965 — Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies · not yet recruiting
Other recruiting trials for Waldenström Macroglobulinemia
Currently open trials in the same condition.
- NCT06986174 — A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemi · Phase 2 · recruiting
- NCT05294731 — Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Deg · Phase 1, PHASE2 · recruiting
- NCT01815749 — Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent · Phase 1 · active not recruiting
Other BeiGene trials
Trials by the same sponsor.
- NCT07169331 — A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglob · Phase 4 · recruiting
- NCT07100938 — A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheum · Phase 2 · active not recruiting
- NCT07005713 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB- · Phase 1 · active not recruiting
- NCT06906809 — Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants · Phase 1 · completed
- NCT06803680 — A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04052854 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BeiGene
- Last refreshed: 23 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04052854.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing